LRRK2 PRIORITY AREA
Why is LRRK2 a Priority?
Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are the greatest known genetic contributor to Parkinson's disease yet discovered. LRRK2 has garnered much excitement among drug makers due to its reported role as a protein kinase in the cell and an apparent enhanced activity caused by Parkinson's disease-associated mutations. Given its strong genetic link and highly "druggable" features, LRRK2 is a key priority focus within the therapeutic development field.
Our Investment in LRRK2 Research
With leadership support from the Brin Wojcicki Foundation, The Michael J. Fox Foundation has made significant efforts to promote a biological and clinical understanding of LRRK2 and to effectively translate research findings into therapies for Parkinson's patients. Our current activities include:
- The LRRK2 Consortium, an international network of investigators focused on understanding the biology and pathological role of LRRK2 in Parkinson's disease. The group focuses on a variety of areas to understand LRRK2 cellular function, protein structure and biochemistry. Members include MJFF awardees and other leading investigators in the field, including representatives from industry. For more information on how to engage the LRRK2 Consortium, please contact us at email@example.com .
- The LRRK2 Cohort Consortium , an international network of investigators studying people with LRRK2 mutations in order to understand clinical LRRK2-associated parkinsonism. See our Access Data and Biospecimens page to learn how you can request clinical data and samples from the consortium. Also, a prospective LRRK2 cohort has been integrated into the MJFF-sponsored Parkinson's Progression Marker Initiative.
- Continuing development of a growing resource of LRRK2 research reagents and models for use by the research community.
- Proactive engagement with industry officials through the MJFF-led LRRK2 Industry Advisory Group in order to help inform the Foundation's strategies for therapeutic translation of LRRK2. For industry representatives who would like to learn more about how to work with MJFF, please email us at firstname.lastname@example.org .
Accelerate Your Research
Access Research Tools
Select from pre-clinical models, reagents, research data and more.
Sign-up for Emails
Receive regular updates on funding opportunities and other resources.
What is LRRK2?